Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

PHASE2CompletedINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

October 31, 2013

Conditions
Chronic Hepatitis C
Interventions
DRUG

PSI-7977

Tablets, oral, 400 mg, once daily

DRUG

Daclatasvir

Tablets, oral, 60 mg, once daily

DRUG

Ribavirin

Tablets, oral, 200 mg

Trial Locations (18)

10021

Weill Cornell Medical College, New York

10468

Bronx Va Medical Center 3c Sub-J, The Bronx

19104

University Of Pennsylvania, Philadelphia

21093

Johns Hopkins University, Lutherville

21202

Mercy Medical Center, Baltimore

22003

Metropolitan Research, Annandale

32610

University Of Florida Hepatology, Gainesville

32803

Orlando Immunology Center, Orlando

33143

Miami Research Associates, South Miami

48109

University Of Michigan Health System, Ann Arbor

53715

Dean Clinic, Madison

74104

Options Health Research, Llc, Tulsa

74135

Healthcare Research Consultants, Tulsa

78215

Alamo Medical Research, San Antonio

80045

University Of Colorado Denver & Hospital, Aurora

92105

Research And Education, Inc., San Diego

92118

Southern California Liver Centers, Coronado

00927

Local Institution, San Juan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pharmasset

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY